These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 401112)

  • 1. Effect of anti-hapten serum on hapten-treated rat tumor.
    Wallace HW; Arai K
    Surg Forum; 1978; 29():126-8. PubMed ID: 401112
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of local immunotherapy of syngeneic rat fibrosarcoma with hapten and antihapten-tumor serum upon nonlocally treated tumor.
    Arai K; Wallace HW
    Cancer Res; 1979 Sep; 39(9):3638-43. PubMed ID: 314334
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of hapten plus antihapten-tumor serum treatment on established rat fibrosarcoma.
    Arai K; Spencer JS; Sohn M; Wallace HW
    Cancer Res; 1979 Jan; 39(1):6-16. PubMed ID: 310708
    [No Abstract]   [Full Text] [Related]  

  • 4. [Future perspectives on tumor-specific immunotherapy using hapten-reactive T cell activity].
    Hamaoka T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):886-96. PubMed ID: 2786376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system.
    Fujiwara H; Aoki H; Yoshioka T; Tomita S; Ikegami R; Hamaoka T
    J Immunol; 1984 Jul; 133(1):509-14. PubMed ID: 6233375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose radiation potentiates the therapeutic efficacy of folate receptor-targeted hapten therapy.
    Sega EI; Lu Y; Ringor M; Leamon CP; Low PS
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):559-66. PubMed ID: 18411004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential.
    Lu Y; You F; Vlahov I; Westrick E; Fan M; Low PS; Leamon CP
    Mol Pharm; 2007; 4(5):695-706. PubMed ID: 17784727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-specific immunotherapy by active immunization with haptenic muramyl dipeptide derivative-coupled tumor cells.
    Fujiwara H; Shima J; Sano H; Kosugi A; Nakajima H; Hamaoka T
    Prog Clin Biol Res; 1987; 244():335-44. PubMed ID: 2958872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of cancer with L-phenylalanine mustard as a hapten.
    Arai K; Wallace HW; Blakemore WS
    Cancer Res; 1973 Aug; 33(8):1914-20. PubMed ID: 4720800
    [No Abstract]   [Full Text] [Related]  

  • 11. Experimental animal models for the study of therapeutic approaches in renal cell carcinoma.
    Hillman GG; Droz JP; Haas GP
    In Vivo; 1994; 8(1):77-80. PubMed ID: 8054515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contact hypersensitivity, humoral immunity, and specific unresponsiveness can be induced in Syrian hamsters with simple haptens.
    Streilein JW; Sullivan S; Thompson S
    J Immunol; 1980 Feb; 124(2):577-85. PubMed ID: 7356707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hapten-directed targeting to single-chain antibody receptors.
    Cheng TL; Liao KW; Tzou SC; Cheng CM; Chen BM; Roffler SR
    Cancer Gene Ther; 2004 May; 11(5):380-8. PubMed ID: 15044963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered glucose metabolism in intact and tumor bearing rats subjected to local hyperthermia.
    Beer-Gabel M; Yerushalmi A
    Bull Cancer; 1981; 68(4):321-7. PubMed ID: 6976200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of in vivo hyporesponsiveness to contact allergens by hapten-modified Ia+ keratinocytes.
    Gaspari AA; Katz SI
    J Immunol; 1991 Dec; 147(12):4155-61. PubMed ID: 1753091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The active immunotherapy of a 3-methylcholanthrene-induced rat tumor with Friend virus-infected (xenogenized) tumor cells.
    Okayasu T; Hosokawa M; Tanabe T; Kobayashi H
    Jpn J Cancer Res; 1986 Aug; 77(8):817-24. PubMed ID: 3093428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
    J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of "tissue-type" specific immunotherapy on colon cancer recurrence in a minimal residual disease model.
    Harte PJ; Steele G; Rayner AA; Corson JM; Munroe AE; King VP; Wilson RE
    Curr Surg; 1982; 39(1):21-3. PubMed ID: 7060396
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of carrier and hapten array on the production of anti-hapten antibodies analyzed by two-dimensional affinity electrophoresis.
    Wang P; Nakamura K
    Electrophoresis; 1998 Jun; 19(8-9):1506-10. PubMed ID: 9694303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cells specific to hapten carrier but not to carrier alone assist in the production of anti-hapten and anti-carrier antibodies.
    Shimizu T; Osaka Y; Banri-Koike C; Yoshida M; Endo K; Furukawa K; Oda M; Murakami A; Ogawa S; Abe R; Azuma T
    Int Immunol; 2007 Oct; 19(10):1157-64. PubMed ID: 17881502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.